O	0	10	Randomized
O	11	18	placebo
O	18	19	-
O	19	29	controlled
O	30	35	study
O	36	38	of
B-intervention	39	50	recombinant
I-intervention	51	56	human
I-intervention	57	68	interleukin
I-intervention	68	69	-
I-intervention	69	71	11
O	72	74	to
O	75	82	prevent
B-condition	83	95	chemotherapy
I-condition	95	96	-
I-condition	96	103	induced
I-condition	104	120	thrombocytopenia
O	121	123	in
O	124	132	patients
O	133	137	with
O	138	144	breast
O	145	151	cancer
O	152	161	receiving
O	162	166	dose
O	166	167	-
O	167	176	intensive
O	177	193	cyclophosphamide
O	194	197	and
O	198	209	doxorubicin
O	209	210	.

O	211	227	Thrombocytopenia
O	228	231	may
O	232	242	compromise
O	243	249	cancer
O	250	259	treatment
O	259	260	,
O	261	268	causing
O	269	281	chemotherapy
O	282	286	dose
O	287	297	reductions
O	297	298	,
O	299	307	schedule
O	308	319	alterations
O	319	320	,
O	321	323	or
O	324	327	the
O	328	332	need
O	333	336	for
O	337	345	platelet
O	346	358	transfusions
O	358	359	.

O	360	362	We
O	363	372	evaluated
O	373	376	the
O	377	385	efficacy
O	386	389	and
O	390	396	safety
O	397	399	of
O	400	411	recombinant
O	412	417	human
O	418	429	interleukin
O	429	430	-
O	430	432	11
O	433	434	(
O	434	438	rhIL
O	438	439	-
O	439	441	11
O	441	442	;
O	443	450	Neumega
O	450	451	,
O	452	460	Genetics
O	461	470	Institute
O	470	471	,
O	472	475	Inc
O	475	476	,
O	477	486	Cambridge
O	486	487	,
O	488	490	MA
O	490	491	)
O	491	492	,
O	493	494	a
O	495	500	novel
O	501	515	thrombopoietic
O	516	522	growth
O	523	529	factor
O	529	530	,
O	531	533	in
O	534	542	reducing
O	543	546	the
O	547	551	need
O	552	555	for
O	556	564	platelet
O	565	577	transfusions
O	578	580	in
O	581	589	patients
O	590	593	who
O	594	601	undergo
O	602	606	dose
O	606	607	-
O	607	616	intensive
O	617	629	chemotherapy
O	629	630	.

B-eligibility	631	636	Women
I-eligibility	637	641	with
I-eligibility	642	650	advanced
I-eligibility	651	657	breast
I-eligibility	658	664	cancer
O	665	673	received
O	674	690	cyclophosphamide
O	691	692	(
O	692	693	3
O	693	694	,
O	694	697	200
O	698	700	mg
O	700	701	/
O	701	703	m2
O	703	704	)
O	705	708	and
O	709	720	doxorubicin
O	721	722	(
O	722	724	75
O	725	727	mg
O	727	728	/
O	728	730	m2
O	730	731	)
O	732	736	plus
O	737	748	granulocyte
O	749	755	colony
O	755	756	-
O	756	767	stimulating
O	768	774	factor
O	775	776	(
O	776	777	G
O	777	778	-
O	778	781	CSF
O	781	782	;
O	783	784	5
O	785	791	microg
O	791	792	/
O	792	794	kg
O	794	795	/
O	795	796	d
O	796	797	)
O	797	798	.

O	799	807	Patients
O	808	812	were
O	813	823	randomized
O	824	826	to
O	827	834	blinded
O	835	844	treatment
O	845	849	with
B-control	850	857	placebo
O	858	860	or
O	861	863	50
O	864	870	microg
O	870	871	/
O	871	873	kg
O	873	874	/
O	874	875	d
O	876	880	rhIL
O	880	881	-
O	881	883	11
O	884	898	subcutaneously
O	899	902	for
O	903	905	10
O	906	908	or
O	909	911	17
O	912	916	days
O	917	922	after
O	923	926	the
O	927	932	first
O	933	936	two
O	937	949	chemotherapy
O	950	956	cycles
O	956	957	.

B-total-participants	958	965	Seventy
I-total-participants	965	966	-
I-total-participants	966	971	seven
O	972	980	patients
O	981	985	were
O	986	996	randomized
O	997	1000	and
O	1001	1011	constitute
O	1012	1015	the
O	1016	1022	intent
O	1022	1023	-
O	1023	1025	to
O	1025	1026	-
O	1026	1031	treat
O	1032	1033	(
O	1033	1036	ITT
O	1036	1037	)
O	1038	1048	population
O	1048	1049	.

B-total-participants	1050	1055	Sixty
I-total-participants	1055	1056	-
I-total-participants	1056	1061	seven
O	1062	1070	patients
O	1071	1072	(
O	1072	1075	the
O	1076	1086	assessable
O	1087	1095	subgroup
O	1095	1096	)
O	1097	1103	either
O	1104	1113	completed
O	1114	1118	both
O	1119	1125	cycles
O	1126	1133	without
O	1134	1135	a
O	1136	1141	major
O	1142	1150	protocol
O	1151	1160	violation
O	1161	1162	(
O	1162	1163	n
O	1164	1165	=
O	1166	1168	62
O	1168	1169	)
O	1170	1172	or
O	1173	1181	received
O	1182	1183	a
O	1184	1192	platelet
O	1193	1204	transfusion
O	1205	1211	before
O	1212	1221	treatment
O	1222	1225	was
O	1226	1238	discontinued
O	1239	1244	after
O	1245	1248	the
O	1249	1254	first
O	1255	1260	cycle
O	1260	1261	.

O	1262	1264	In
O	1265	1268	the
O	1269	1272	ITT
O	1273	1283	population
O	1283	1284	,
O	1285	1289	rhIL
O	1289	1290	-
O	1290	1292	11
O	1293	1306	significantly
O	1307	1316	decreased
O	1317	1320	the
O	1321	1332	requirement
O	1333	1336	for
B-outcome	1337	1345	platelet
I-outcome	1346	1358	transfusions
O	1358	1359	;
B-iv-bin-abs	1360	1362	27
O	1363	1365	of
B-intervention-participants	1366	1368	40
O	1369	1370	(
B-iv-bin-percent	1370	1372	68
I-iv-bin-percent	1372	1373	%
O	1373	1374	)
O	1375	1383	patients
O	1384	1387	who
O	1388	1396	received
O	1397	1401	rhIL
O	1401	1402	-
O	1402	1404	11
O	1405	1408	did
O	1409	1412	not
O	1413	1420	require
O	1421	1433	transfusions
O	1433	1434	,
O	1435	1443	compared
O	1444	1448	with
B-cv-bin-abs	1449	1451	15
O	1452	1454	of
B-control-participants	1455	1457	37
O	1458	1459	(
B-cv-bin-percent	1459	1461	41
I-cv-bin-percent	1461	1462	%
O	1462	1463	)
O	1464	1466	in
O	1467	1470	the
O	1471	1478	placebo
O	1479	1484	group
O	1485	1486	(
O	1486	1487	P
O	1488	1489	=
O	1490	1491	.
O	1491	1493	04
O	1493	1494	)
O	1494	1495	.

O	1496	1505	Treatment
O	1506	1510	with
O	1511	1515	rhIL
O	1515	1516	-
O	1516	1518	11
O	1519	1532	significantly
O	1533	1540	reduced
O	1541	1544	the
B-outcome	1545	1550	total
I-outcome	1551	1557	number
I-outcome	1558	1560	of
I-outcome	1561	1569	platelet
I-outcome	1570	1582	transfusions
I-outcome	1583	1591	required
O	1592	1594	in
O	1595	1598	the
O	1599	1609	assessable
O	1610	1618	subgroup
O	1619	1620	(
O	1620	1621	P
O	1622	1623	=
O	1624	1625	.
O	1625	1627	03
O	1627	1628	)
O	1629	1632	and
O	1633	1636	the
B-outcome	1637	1641	time
I-outcome	1642	1644	to
I-outcome	1645	1653	platelet
I-outcome	1654	1662	recovery
O	1663	1665	to
O	1666	1670	more
O	1671	1675	than
O	1676	1678	50
O	1678	1679	,
O	1679	1682	000
O	1682	1683	/
O	1683	1689	microL
O	1690	1692	in
O	1693	1696	the
O	1697	1703	second
O	1704	1709	cycle
O	1710	1711	(
O	1711	1712	P
O	1713	1714	=
O	1715	1716	.
O	1716	1718	01
O	1718	1719	)
O	1719	1720	.

O	1721	1725	Most
B-outcome	1726	1733	adverse
I-outcome	1734	1740	events
O	1741	1751	associated
O	1752	1756	with
O	1757	1761	rhIL
O	1761	1762	-
O	1762	1764	11
O	1765	1769	were
O	1770	1780	reversible
O	1780	1781	,
O	1782	1786	mild
O	1787	1789	to
O	1790	1798	moderate
O	1799	1801	in
O	1802	1810	severity
O	1810	1811	,
O	1812	1815	and
O	1816	1822	likely
O	1823	1830	related
O	1831	1833	to
O	1834	1839	fluid
O	1840	1849	retention
O	1849	1850	.

O	1851	1855	rhIL
O	1855	1856	-
O	1856	1858	11
O	1859	1861	is
O	1862	1866	safe
O	1867	1870	and
O	1871	1880	effective
O	1881	1883	in
O	1884	1892	reducing
O	1893	1902	treatment
O	1902	1903	-
O	1903	1913	associated
O	1914	1930	thrombocytopenia
O	1931	1934	and
O	1935	1938	the
O	1939	1943	need
O	1944	1947	for
O	1948	1956	platelet
O	1957	1969	transfusions
O	1970	1972	in
O	1973	1981	patients
O	1982	1985	who
O	1986	1993	undergo
O	1994	1998	dose
O	1998	1999	-
O	1999	2008	intensive
O	2009	2021	chemotherapy
O	2021	2022	,
O	2023	2026	and
O	2027	2031	thus
O	2032	2035	may
O	2036	2042	permit
O	2043	2055	chemotherapy
O	2056	2058	to
O	2059	2061	be
O	2062	2074	administered
O	2075	2077	as
O	2078	2085	planned
O	2086	2088	at
O	2089	2097	intended
O	2098	2103	doses
O	2104	2107	and
O	2108	2115	thereby
O	2116	2124	maximize
O	2125	2128	the
O	2129	2138	potential
O	2139	2142	for
O	2143	2144	a
O	2145	2155	successful
O	2156	2163	outcome
O	2163	2164	.
